gabapentin has been researched along with Agitation, Psychomotor in 11 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve patients with moderate to severe dementia and severe behavioral disorders were treated with open-label gabapentin (200-1,200 mg/day) for 8 weeks in a prospective case-series design." | 9.09 | Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. ( Herrmann, N; Lanctôt, K; Myszak, M, 2000) |
| "We aimed to report our institution's experience with gabapentin therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting." | 7.96 | Gabapentin for pain, movement disorders, and irritability in neonates and infants. ( Burnsed, JC; Heinan, K; Letzkus, L; Zanelli, S, 2020) |
| "Our patient, a 77-year-old Czech woman with incipient vascular dementia, received gabapentin 400mg at bedtime for 6 months and showed convincing improvement." | 7.77 | Gabapentin in the treatment of dementia-associated nocturnal agitation. ( Busek, P; Buskova, J; Nevsimalova, S, 2011) |
| " The aim of the present study was to examine the role of Gabapentin oral solution in attenuating desflurane associated EA in children after strabismus surgery under general anesthesia." | 5.27 | The role of Gabapentin oral solution in decreasing desflurane associated emergence agitation and delirium in children after stabismus surgery, a prospective randomized double-blind study. ( Adel, G; Al Menesy, T; Badawy, AA; Badawy, YA; Kasem, SA; Mokhtar, AM; Rashwan, D, 2018) |
| "Twelve patients with moderate to severe dementia and severe behavioral disorders were treated with open-label gabapentin (200-1,200 mg/day) for 8 weeks in a prospective case-series design." | 5.09 | Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. ( Herrmann, N; Lanctôt, K; Myszak, M, 2000) |
| " The purpose of this review of the literature is to assess the interest and the limits of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate, oxcarbazepine) in the treatment of the so-called "noncognitive" symptoms of dementia." | 4.84 | [Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)]. ( Pinheiro, D, 2008) |
| "We aimed to report our institution's experience with gabapentin therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting." | 3.96 | Gabapentin for pain, movement disorders, and irritability in neonates and infants. ( Burnsed, JC; Heinan, K; Letzkus, L; Zanelli, S, 2020) |
| "Our patient, a 77-year-old Czech woman with incipient vascular dementia, received gabapentin 400mg at bedtime for 6 months and showed convincing improvement." | 3.77 | Gabapentin in the treatment of dementia-associated nocturnal agitation. ( Busek, P; Buskova, J; Nevsimalova, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Badawy, AA | 1 |
| Kasem, SA | 1 |
| Rashwan, D | 1 |
| Al Menesy, T | 1 |
| Adel, G | 1 |
| Mokhtar, AM | 1 |
| Badawy, YA | 1 |
| Burnsed, JC | 1 |
| Heinan, K | 1 |
| Letzkus, L | 1 |
| Zanelli, S | 1 |
| Pinheiro, D | 1 |
| Buskova, J | 1 |
| Busek, P | 1 |
| Nevsimalova, S | 1 |
| Regan, WM | 1 |
| Gordon, SM | 1 |
| Goldenberg, G | 1 |
| Kahaner, K | 1 |
| Basavaraju, N | 1 |
| Rangu, S | 1 |
| Low, RA | 1 |
| Brandes, M | 1 |
| Herrmann, N | 1 |
| Lanctôt, K | 1 |
| Myszak, M | 1 |
| Roane, DM | 1 |
| Feinberg, TE | 1 |
| Meckler, L | 1 |
| Miner, CR | 1 |
| Scicutella, A | 1 |
| Rosenthal, RN | 1 |
| Bozikas, V | 1 |
| Bascialla, F | 1 |
| Yulis, P | 1 |
| Savvidou, I | 1 |
| Karavatos, A | 1 |
| Megna, JL | 1 |
| Devitt, PJ | 1 |
| Sauro, MD | 1 |
| Dewan, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Gabapentin Oral Solution in Decreasing Desflurane Associated Emergence Agitation and Delirium in Children After Strabismus Surgery: A Prospective Randomized Double-blind Study[NCT03347916] | 75 participants (Anticipated) | Interventional | 2017-01-05 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gabapentin and Agitation, Psychomotor
| Article | Year |
|---|---|
[Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)].
Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dementia; Fructose; Gabap | 2008 |
3 trials available for gabapentin and Agitation, Psychomotor
| Article | Year |
|---|---|
The role of Gabapentin oral solution in decreasing desflurane associated emergence agitation and delirium in children after stabismus surgery, a prospective randomized double-blind study.
Topics: Administration, Oral; Anesthesia, General; Anesthetics, Inhalation; Child; Child, Preschool; Desflur | 2018 |
Effectiveness of gabapentin for the treatment of behavioral disorders in dementia.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Anti-Anxiety Agents; Behavioral Symptoms; Cyclohexanecarb | 2000 |
Gabapentin's effect on agitation in severely and persistently mentally ill patients.
Topics: Acetates; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2002 |
7 other studies available for gabapentin and Agitation, Psychomotor
| Article | Year |
|---|---|
Gabapentin for pain, movement disorders, and irritability in neonates and infants.
Topics: Analgesics; Female; Gabapentin; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Mal | 2020 |
Gabapentin in the treatment of dementia-associated nocturnal agitation.
Topics: Aged; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Darkness; Dementia; Female; Gabapent | 2011 |
Gabapentin for behavioral agitation in Alzheimer's disease.
Topics: Acetates; Aged; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Admini | 1997 |
Gabapentin for disruptive behaviour in an elderly demented patient.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dementia; D | 1998 |
Gabapentin for the management of agitation.
Topics: Acetates; Aggression; Amines; Cyclohexanecarboxylic Acids; GABA Agonists; Gabapentin; gamma-Aminobut | 1999 |
Treatment of dementia-associated agitation with gabapentin.
Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic | 2000 |
Gabapentin for behavioral dyscontrol with mental retardation.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Drug Th | 2001 |